SynAct Pharma AB Stock: price and insider trades · Sweden

SynAct Pharma AB, classified in the Health Care sector, is a listed company based in Medicon Village, Sweden, founded in 2012. Its insiders report their share dealings to Finansinspektionen. Between 18 October 2025 and 18 October 2026, 6 insiders published 6 filings.

Open-market activity splits into 4 purchases totalling €27k and 2 sales totalling €797k; 4 insiders sit on the buying side and 2 insiders on the selling side. Taken together, the sales exceed the purchases by €770k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 2 board members, 1 senior executive and 1 chief executive. At €558k, the sale published on 7 September 2026 by Thomas Jonassen is the largest of the period (0.64% of market cap).

With 6 filings in twelve months, the company is quieter than the median of 7 filings across the 886 companies we follow on the same exchange. Since 2021, the database holds 4 purchases and 3 sales by insiders of the company.

The data flag 2 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 9 March 2026, 223 days ago. Filings reach the Finansinspektionen feed a median of 5 days after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade.

Elsewhere in the same sector, our signals recently picked up insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.